Description
Ponesimod is a potent agonist of sphingosine-1-phosphate receptor 1 (S1P1) receptor. It reduces the circulating lymphocytes at a dose of 3-100 mg/kg in a rat model. It selectively activates S1P1 in a GTPγS assay with an EC₅₀ of 5.7 nM. It has been recently approved for the treatment of multiple sclerosis.
Ponesimod is a potent agonist of sphingosine-1-phosphate receptor 1 (S1P1) receptor. It reduces the circulating lymphocytes at a dose of 3-100 mg/kg in a rat model. It selectively activates S1P1 in a GTPγS assay with an EC₅₀ of 5.7 nM. It has been recently approved for the treatment of multiple sclerosis.
Alternate Name/Synonyms: ACT-128800, (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one; (2Z,5Z)-5-(3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one
Appearance: Light yellow to yellow solid
Formulation:
CAS Number: 854107-55-4
Structure Available?: TRUE
Peptide sequence:
Salt Form: FALSE
Molecular Formula: C₂₃H₂₅ClN₂O₄S
Molecular Weight: 460.97
Cell-Permeable?: True
Purity: ≥ 98% (HPLC)
Solubilities: ~5 mg/ml in DMSO or DMF
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A potent agonist of sphingosine-1-phosphate receptor 1 (S1P1) receptor
MDL Number: MFCD18207776
PubChem CID: 11363176
SMILES: CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C
InChi: InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
InChi Key: LPAUOXUZGSBGDU-ULCCENQXSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |